0.78
+0.027(+3.56%)
Currency In USD
| Previous Close | 0.76 |
| Open | 0.76 |
| Day High | 0.8 |
| Day Low | 0.7 |
| 52-Week High | 3.73 |
| 52-Week Low | 0.62 |
| Volume | 3.75M |
| Average Volume | 4.19M |
| Market Cap | 283.7M |
| PE | -1.06 |
| EPS | -0.74 |
| Moving Average 50 Days | 1.16 |
| Moving Average 200 Days | 1.66 |
| Change | 0.03 |
If you invested $1000 in Lexicon Pharmaceuticals, Inc. (LXRX) 10 years ago, it would be worth $113.74 as of December 26, 2024 at a share price of $0.725. Whereas If you bought $1000 worth of Lexicon Pharmaceuticals, Inc. (LXRX) shares 5 years ago, it would be worth $176.28 as of December 26, 2024 at a share price of $0.725.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
GlobeNewswire Inc.
Dec 20, 2024 9:30 PM GMT
Confirms Previously Disclosed and Anticipated FDA DecisionTHE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and D
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
GlobeNewswire Inc.
Nov 26, 2024 1:00 PM GMT
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2025 THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (N
Lexicon Pharmaceuticals to Participate in December Investor Conferences
GlobeNewswire Inc.
Nov 25, 2024 9:15 PM GMT
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investo